Hikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is GBX 2,325 ($31.13).

Several equities research analysts have recently commented on the company. Berenberg Bank raised Hikma Pharmaceuticals to a “buy” rating and boosted their price target for the stock from GBX 2,100 ($28.12) to GBX 2,400 ($32.14) in a research note on Monday, September 2nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 2,750 ($36.82) target price on shares of Hikma Pharmaceuticals in a research report on Tuesday, June 18th.

Hikma Pharmaceuticals Trading Up 0.3 %

Shares of HIK stock opened at GBX 1,867 ($25.00) on Thursday. The business’s fifty day moving average price is GBX 1,944.85 and its 200 day moving average price is GBX 1,917.73. The firm has a market capitalization of £4.14 billion, a PE ratio of 2,872.31, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.48, a current ratio of 1.66 and a quick ratio of 1.27. Hikma Pharmaceuticals has a 1-year low of GBX 1,711 ($22.91) and a 1-year high of GBX 2,165 ($28.99).

Hikma Pharmaceuticals Cuts Dividend

The firm also recently declared a dividend, which was paid on Friday, September 20th. Shareholders of record on Thursday, August 15th were issued a $0.32 dividend. This represents a yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 15th. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is 9,538.46%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.